Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02640209
Title Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pennsylvania

chronic lymphocytic leukemia/small lymphocytic lymphoma


CART19 cells

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.